文献速递儿童感染儿童呼吸

儿童非MIS-C COVID-19住院早期使用类固醇与结局的关联

Association of Early Steroid Administration With Outcomes of Children Hospitalized for COVID-19 Without Multisystem Inflammatory Syndrome in Children.
PubMed 文献 · JAMA Pediatr · 2022-10-03

该队列研究分析7国58家医院1163例非MIS-C COVID-19住院儿童,184例(15.8%)在入院2天内使用类固醇。多变量线性回归和倾向评分匹配显示,早期类固醇治疗与住院时长、ICU时长、退热及炎症指标正常化均无显著关联。

要点

  • 非MIS-C COVID-19住院儿童中,15.8%在入院2天内接受类固醇治疗。
  • 早期类固醇使用与ICU时长、第3天退热及炎症指标正常化均无显著关联。

核心结论

  • 在非MIS-C COVID-19住院儿童异质性队列中,入院2天内类固醇治疗与住院时长无统计学显著关联。

研究设计与样本

  • 回顾性队列研究,分析2020年3月至2021年9月7国58家医院参与的VIRUS COVID-19注册数据,纳入1163例18岁以下非MIS-C COVID-19住院儿童。

主要发现

  • 1163例患者中位年龄7岁(IQR 0.9-14.3),男性601/1163(51.7%),非西班牙裔白人392/1163(33.8%),西班牙裔324/1163(27.9%)。
  • 184例(15.8%)在入院2天内接受类固醇,979例(84.2%)未接受;658例(56.5%)住院期间需要呼吸支持。
  • 类固醇组患者年龄更大、病情更重,需要呼吸和血管活性支持的比例更高。
  • 亚组分析(住院≥2天n=729、入院时呼吸支持n=286、倾向评分匹配)及ICU时长、第3天退热、炎症指标正常化均无显著关联。

临床怎么用

  • 对于非MIS-C COVID-19住院儿童,早期使用类固醇不应常规用于缩短住院时长或改善ICU时长、退热及炎症指标。

局限性

  • 为回顾性队列研究,类固醇组病情更重,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is limited evidence for therapeutic options for pediatric COVID-19 outside of multisystem inflammatory syndrome in children (MIS-C). OBJECTIVE: To determine whether the use of steroids within 2 days of admission for non-MIS-C COVID-19 in children is associated with hospital length of stay (LOS). The secondary objective was to determine their association with intensive care unit (ICU) LOS, inflammation, and fever defervescence. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed data retrospectively for children (<18 years) who required hospitalization for non-MIS-C COVID-19. Data from March 2020 through September 2021 were provided by 58 hospitals in 7 countries who participate in the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) COVID-19 registry. EXPOSURE: Administration of steroids within 2 days of admission. MAIN OUTCOMES AND MEASURES: Length of stay in the hospital and ICU. Adjustment for confounders was done by mixed linear regression and propensity score matching. RESULTS: A total of 1163 patients met inclusion criteria and had a median (IQR) age of 7 years (0.9-14.3). Almost half of all patients (601/1163, 51.7%) were male, 33.8% (392/1163) were non-Hispanic White, and 27.9% (324/1163) were Hispanic. Of the study population, 184 patients (15.8%) received steroids within 2 days of admission, and 979 (84.2%) did not receive steroids within the first 2 days. Among 1163 patients, 658 (56.5%) required respiratory support during hospitalization. Overall, patients in the steroids group were older and had greater severity of illness, and a larger proportion required respiratory and vasoactive support. On multivariable linear regression, after controlling for treatment with remdesivir within 2 days, country, race and ethnicity, obesity and comorbidity, number of abnormal inflammatory mediators, age, bacterial or viral coinfection, and disease severity according to ICU admission within first 2 days or World Health Organization ordinal scale of 4 or higher on admission, with a random intercept for the site, early steroid treatment was not significantly associated with hospital LOS (exponentiated coefficient, 0.94; 95% CI, 0.81-1.09; P = .42). Separate analyses for patients with an LOS of 2 days or longer (n = 729), those receiving respiratory support at admission (n = 286), and propensity score-matched patients also showed no significant association between steroids and LOS. Early steroid treatment was not associated with ICU LOS, fever defervescence by day 3, or normalization of inflammatory mediators. CONCLUSIONS AND RELEVANCE: Steroid treatment within 2 days of hospital admission in a heterogeneous cohort of pediatric patients hospitalized for COVID-19 without MIS-C did not have a statistically significant association with hospital LOS.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Tripathi S, Nadiger M, McGarvey JS, et al. Association of Early Steroid Administration With Outcomes of Children Hospitalized for COVID-19 Without Multisystem Inflammatory Syndrome in Children. JAMA Pediatr. 2022. PMID: 36190706. doi:10.1001/jamapediatrics.2022.3611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。